

REMARKS

Claims 1-26 are pending with claims 24-26 added by this paper. Applicants note that claim 12 has been amended for clarification and to conform this claim to typical U.S. prosecution practice. This amendment does not narrow its scope.

Applicants hereby elect with traverse claim 12 (Group II) drawn to compounds of formula II. Applicants traverse this requirement because the Examiner has not established that searching all claims would constitute an undue burden.

Moreover, Applicants elect with traverse the following species:

“5-Ethyl-5 β -androst-9(11)-ene-3 β ,17 β -diol”

Applicants traverse the election requirement on the basis that the Examiner has not provided any evidence that an undue searching burden would be necessary to search the full scope of the claims.

Also, Applicants respectfully request the Examiner to acknowledge receipt of the priority documents received from the International Bureau in the next paper from the Office.

No fee is believed to be due with this response, however, the Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402

Respectfully submitted,



James E. Ruland, Reg. No. 37,432
Attorney for Applicants

MILLEN, WHITE, ZELANO &
BRANIGAN, P.C.
Arlington Courthouse Plaza 1, Suite 1400
2200 Clarendon Boulevard
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: SCH-1867

Date: September 29, 2003

K:\sch\1867\Rsp to RR.doc